ARTICLE | Company News
KS Biomedix, Schering in cancer deal
June 7, 2001 7:00 AM UTC
KS Biomedix (LSE:KSB) will use its high affinity antibody technology to create single-chain antibodies against an SHR angiogenesis cancer target. SHR will evaluate resulting antibodies and has the opt...